Previous 10 | Next 10 |
WARREN, N.J. , April 9, 2020 /PRNewswire/ -- Celularity Inc. ("Celularity" or the "Company"), a clinical-stage company developing allogeneic cellular therapies from human placentas, today announced the expansion of its existing collaborative license agreement with United Therapeutics...
As the health crisis spirals into a financial one, the liquidation and panic selling have indiscriminately hit sectors across the board. The biotechs were no exception, with the S&P Biotech ETF ( XBI ) plummeting -20% on the year in tandem with the S&P 500 (SPY). Source: WingCapital...
Today, we will see why Arena Pharmaceuticals (ARNA) is an attractive pick in March 2020. Company overview Arena Pharmaceuticals is a biopharmaceutical company with four clinical-stage assets, Etrasimod, Olorinab, APD418, and Ralinepag partnership, which are being evaluated across eight d...
Appili Therapeutics (APLI CN) initiated with Buy rating and C$4 (602% upside) price target at Maxim Group. More news on: Aphria Inc., Codexis, Inc., HEXO Corp., Healthcare stocks news, Stocks on the move, , Read more ...
Under Priority Review and Breakthrough Therapy status, the FDA approves privately held Boehringer Ingelheim's Ofev (nintedanib) oral capsules for the treatment of patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait). More news o...
Investment Thesis United Therapeutics (UTHR) holds a sizable chunk of the pulmonary arterial hypertension ("PAH") treatment market - the company has been active in this field since its current best-selling drug Remodulin was approved by the FDA back in 2002. PAH is a rare disease that affe...
The Magic Formula by Joel Greenblatt has been a subject of my writing in the past . What used to bug me is that the screen included many microcaps and odd stocks such as royalty trusts. Therefore I decided to set the minimum market cap at $2.5bn. Overall, I am pleased with the new result be...
United Therapeutics Corporation (UTHR) Q4 2019 Earnings Conference Call February 26, 2020, 09:00 AM ET Company Participants Dewey Steadman - Head of IR James Edgemond - CFO and Treasurer Martine Rothblatt - Chairman and CEO Michael Benkowitz - President and COO Leigh Peterson...
United Therapeutics (NASDAQ: UTHR ): Q4 Non-GAAP EPS of $1.96 misses by $1.43 ; GAAP EPS of $1.20 misses by $1.31 . More news on: United Therapeutics Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 26, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2019 . Full year net revenue decreased 11% to $1,449 million...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...